Letaplimab

DB16679InvestigationalProtein Based Therapies

Letaplimab is under investigation in clinical trial NCT04485052 (Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia).

Mechanism: Pharmacologically active on Leukocyte surface antigen CD47
Curator reviewed
Code names: Human anti-CD47 monoclonal antibody (IBI-188) · IBI-188

Resolves to

Compound

UNIIBDN84I1TFECAS2283356-07-8

Targets

Q08722CD47

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Letaplimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account